XLO
Xilio Therapeutics
$9.09
+$0.44 (+5.09%)Jul 27, 2026
Key metrics
The numbers that frame XLO today
- Market cap
- $54.38M
- P/E (TTM)
- -1.7
- EV / FCF
- 1.6
- Gross margin
- 100%
- EV / Sales
- -1.7
- ROIC
- 108.7%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $6.47
- 52wk High
- $12.74
Growth
Revenue and earnings trend for XLO
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about XLO
Is Xilio Therapeutics a good buy?
No. Xilio Therapeutics has poor quality and weak momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case.
What is the market capitalization of XLO?
Xilio Therapeutics's market capitalization is $54.38M.
What is the P/E ratio for XLO stock?
Xilio Therapeutics's current P/E ratio is -1.7.
What is the 52-week high for XLO stock?
The 52-week high for Xilio Therapeutics is $12.74. The current close of $9.09 is 28.6% below that high.
What is the 52-week low for XLO stock?
The 52-week low for Xilio Therapeutics is $6.47. The current close of $9.09 is 40.6% above that low.
Does XLO stock pay dividends?
Xilio Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for XLO?
Xilio Therapeutics's Debt / Equity ratio is 0.09.